The next steps will result in the rise of the industry in the pharmaceutical market with the increase of its productive capacity and expansion of its portfolio. Photo: AEN
Prati-Donaduzzi pharmaceutical industry, based in Toledo, in the western region of Paraná, consolidates itself as the largest generic drugs manufacturer in Brazil*. A partnership with the Government of the State of Paraná was made official on Wednesday (05), at Iguaçu Palace in Curitiba, enabling the investment of R$ 650 million by the company in the State.
The next steps will result in the rise of the industry in the pharmaceutical market with the increase of its productive capacity and expansion of its portfolio. In the coming years, Prati-Donaduzzi will invest in the construction of a new high-tech manufacturing unit at its headquarters, modernization of current plants, as well as in Research, Development and Innovation (RD&I).
“We have always believed in the transformative power of entrepreneurship as an engine of development. With these investments, we will generate jobs, economic and social advances and expand access to medicines for the population, fulfilling our mission”, evaluates the Board Chairman, Luiz Donaduzzi.
The protocol of intentions signed with the Government of Paraná was fundamental for the industry's decision. After evaluating proposals from governments in other states, Prati opted for valuing the solid partnership with Paraná, where it began its history 26 years ago.
Prati ensured the support of the State Government for meeting three criteria: job creation, innovation and increased tax collection in the medium and long term. "We are happy to continue investing in Paraná and contributing to regional development", reinforces Donaduzzi.
The partnership signed with Invest Paraná, former Paraná Development Agency (APD), provides for commitments from both parties. The State will grant tax and tax benefits to the company. In return, the pharmaceutical company will invest R$ 650 million in its growth project, contemplating the construction and expansion of physical structure and the acquisition of state-of-the-art equipment, contributing to the state's economy and generating hundreds of new jobs.
For the pharmaceutical company's CEO, Eder Fernando Maffissoni, this moment highlights the potential of the industry that stands out as a reference in the production of medicines and plans to grow 40% in its production capacity, reaching 17 billion doses per year.
“We are big and we will be even bigger. This is the result of a carefully conceived strategic planning. We are proud of having and keeping the title of the largest generic producer in Brazil. The investments ensure that we can bring health and well-being to millions of Brazilians, through pharmaceutical products of high quality and reliability”, ends Maffissoni.
*IQVIA MAT DEZ/2019 PMB + NRC Doses Terapêuticas